Adalimumab/etanerceptLatent tuberculosis infection: 7 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2013年 / 1444卷 / 1期

关键词：

D O I：

10.1007/s40278-013-2024-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：6 / 6

相关论文

共 50 条

[1] Adalimumab/etanerceptLatent tuberculosis infection: 6 case reports
Reactions Weekly, 2018, 1724 (1) : 16 - 16
[2] Adalimumab/ustekinumabLatent tuberculosis infection: 4 case reports
Reactions Weekly, 2021, 1846 (1) : 15 - 15
[3] Adalimumab/secukinumabLatent tuberculosis infection and active tuberculosis: 9 case reports
Reactions Weekly, 2022, 1917 (1) : 28 - 28
[4] Adalimumab/etanerceptActive pulmonary tuberculosis and latent tuberculosis infection: 10 case reports
Reactions Weekly, 2015, 1568 (1) : 17 - 17
[5] Adalimumab/etanercept/infliximabLate onset tuberculosis infection: 11 case reports
Reactions Weekly, 2014, 1517 (1) : 20 - 20
[6] Adalimumab/etanercept/infliximabReactivation of latent tuberculosis infection and pleuropulmonary tuberculosis: 15 case reports
Reactions Weekly, 2023, 1963 (1) : 24 - 24
[7] EtanerceptLatent tuberculosis reactivation: case report
Reactions Weekly, 2020, 1798 (1) : 123 - 123
[8] Adalimumab/ustekinumab/vedolizumabCOVID-19 infection: 7 case reports
Reactions Weekly, 2022, 1894 (1) : 22 - 22
[9] Adalimumab/infliximabActive tuberculosis: 15 case reports
Reactions Weekly, 2017, 1678 (1) : 13 - 13
[10] Adalimumab/infliximabMiliary tuberculosis: 4 case reports
Reactions Weekly, 2015, 1551 (1) : 15 - 15

← 1 2 3 4 5 →